|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM153782501 |
| 003 |
DE-627 |
| 005 |
20231223064711.0 |
| 007 |
tu |
| 008 |
231223s2005 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n0513.xml
|
| 035 |
|
|
|a (DE-627)NLM153782501
|
| 035 |
|
|
|a (NLM)15721840
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Marsik, Claudia
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Endotoxemia enhances expression of the signaling receptor (GP130) on protein and molecular level
|
| 264 |
|
1 |
|c 2005
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 19.04.2005
|
| 500 |
|
|
|a Date Revised 17.11.2005
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Interleukin 6 (IL-6) performs a prominent role during sepsis. To examine the molecular regulation of IL-6, IL-6 receptor, and signaling receptor gp130 during endotoxemia, nine healthy young volunteers received a bolus injection of lipopolysaccharide (LPS) on day 1 and saline on day 2 in a double blind, randomized, placebo-controlled trial. LPS enhanced IL-6 release 300-fold. IL-6 mRNA expression was not significantly altered in blood samples at any time after LPS infusion in vivo, while incubation of whole blood with 50 pg/ml LPS up-regulated IL-6 mRNA levels 8000- to 50,000-fold in vitro. LPS infusion increased synthesis of gp130 mRNA 5.5-fold compared to baseline at 4 h (P < 0.05), while no significant change was observed in the placebo period (P = 0.001 between groups). LPS increased the percentage of gp130 positive neutrophils gp130 700% over baseline at 8 h (P < 0.01 versus baseline and placebo). IL-6 receptor levels were not significantly altered by low-grade endotoxemia. In conclusion, endotoxemia up-regulates gp130 expression in vivo and in vitro. Quantification of IL-6 mRNA expression in circulating leukocytes is unlikely a suitable marker for monitoring of endotoxemia
|
| 650 |
|
4 |
|a Clinical Trial
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Randomized Controlled Trial
|
| 650 |
|
7 |
|a Antigens, CD
|2 NLM
|
| 650 |
|
7 |
|a IL6ST protein, human
|2 NLM
|
| 650 |
|
7 |
|a Interleukin-6
|2 NLM
|
| 650 |
|
7 |
|a Lipopolysaccharides
|2 NLM
|
| 650 |
|
7 |
|a Membrane Glycoproteins
|2 NLM
|
| 650 |
|
7 |
|a RNA, Messenger
|2 NLM
|
| 650 |
|
7 |
|a Receptors, Interleukin-6
|2 NLM
|
| 650 |
|
7 |
|a Cytokine Receptor gp130
|2 NLM
|
| 650 |
|
7 |
|a 133483-10-0
|2 NLM
|
| 700 |
1 |
|
|a Halama, Thomas
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Cardona, Francesco
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Schlifke, Irene
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Mittermayer, Friedrich
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Jilma, Bernd
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 114(2005), 3 vom: 25. März, Seite 293-8
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:114
|g year:2005
|g number:3
|g day:25
|g month:03
|g pages:293-8
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 114
|j 2005
|e 3
|b 25
|c 03
|h 293-8
|